Xalud Therapeutics’ Novel, Immune-Modulatory Platform

Time: 4:00 pm
day: Day One

Details:

  • Overview of immunology of pain at peripheral and central sites
  • Key importance of proinflammatory mediators peripherally and centrally argues for anti-inflammatory solution using interleukin-10 (IL-10)
  • Efficacy of non-viral IL-10 gene therapy (XT-150) in rodent models of neuropathic pain, now translating to human clinical trials
  • Translation of XT-150 to osteoarthritis in companion animals and now human clinical trials

Speakers: